Trade the trade, live the trade....weeeeeeeeee
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
We tested new 52wk highs today. 005+ tomorrow most likely
yup 005s getting closer
$CCBT looks like dilution slowed down. lookin much better.. MM ALPS all the way to 01
nice continuation from yesterday.
its coming this week
0017 nice pb
nice pick
Tiny ss should it
Exactly. This alone should place it at least 01s
So your friend went to the 3am 1 minute hearing ?? Lmfao yea okay
$PPCB 008 ALERT MUST SEE DD!!!
-The only QB company under 0.01 which develop cancer treatment successfully.
-Dr. Ralf Brandt (PhD) the founder of Vivo Pharm a multi-billion pharma company joined the advisory board
Dr. Brandt is the co-founder of vivoPharm. He is a biochemist and cell biologist with over 15 years experience in research programs of experimental oncology. Furthermore, he has immense experience in in vivo pharmacology and anti-cancer drug profiling. He received his Licence (BSc in Biochemistry and Animal Physiology) in 1986, and his PhD (in Biochemistry) in 1991 from the Martin-Luther University of Halle-Wittenberg, Germany. Dr. Brandt was employed at research positions at the National Cancer Institute in Bethesda, MD, USA and at Schering AG, Germany. Since 1990, Dr. Brandt has been active in the field of preclinical oncology. He led the Tumour Biology program at Novartis Pharma AG, Switzerland and established several transgenic mouse lines developing tumours under the control of oncogenes. During Dr. Brandt’s long career in the pharmaceutical industry he has acquired significant knowledge and expertise in leading business units and representation of services to the pre-clinical research market. Dr. Brandt is a member of the Scientific Advisory Board at Receptor Inc. in Toronto Canada and Propanc in Melbourne VIC, Australia.
-Cancer patent was granted in India
https://www.otcmarkets.com/stock/PPCB/news/Propanc-Biopharmas-Foundation-Patent-Granted-in-India?id=213856" rel="nofollow" target="_blank" >https://www.otcmarkets.com/stock/PPCB/news/Propanc-Biopharmas-Foundation-Patent-Granted-in-India?id=213856[tag]insert-text-here[/NEWS]
DD: Undervalued Bio company on the verge of a huge break in the clinical trials buyout imminent.
PPCB 008 MUST SEE DD
-The only QB company under 0.01 which develop cancer treatment successfully.
-Dr. Ralf Brandt (PhD) the founder of Vivo Pharm a multi-billion pharma company joined the advisory board
Dr. Brandt is the co-founder of vivoPharm. He is a biochemist and cell biologist with over 15 years experience in research programs of experimental oncology. Furthermore, he has immense experience in in vivo pharmacology and anti-cancer drug profiling. He received his Licence (BSc in Biochemistry and Animal Physiology) in 1986, and his PhD (in Biochemistry) in 1991 from the Martin-Luther University of Halle-Wittenberg, Germany. Dr. Brandt was employed at research positions at the National Cancer Institute in Bethesda, MD, USA and at Schering AG, Germany. Since 1990, Dr. Brandt has been active in the field of preclinical oncology. He led the Tumour Biology program at Novartis Pharma AG, Switzerland and established several transgenic mouse lines developing tumours under the control of oncogenes. During Dr. Brandt’s long career in the pharmaceutical industry he has acquired significant knowledge and expertise in leading business units and representation of services to the pre-clinical research market. Dr. Brandt is a member of the Scientific Advisory Board at Receptor Inc. in Toronto Canada and Propanc in Melbourne VIC, Australia.
-Cancer patent was granted in India
https://www.otcmarkets.com/stock/PPCB/news/Propanc-Biopharmas-Foundation-Patent-Granted-in-India?id=213856" rel="nofollow" target="_blank" >https://www.otcmarkets.com/stock/PPCB/news/Propanc-Biopharmas-Foundation-Patent-Granted-in-India?id=213856[tag]insert-text-here[/NEWS]
DD: Undervalued Bio company on the verge of a huge break in the clinical trials buyout imminent.
DLYT 0057 +78%... $72 mil contract
DLYT 005 ALERT!! MUST READ DD
DLYT revenues just getting bigger and bigger!
~Net revenue for the quarter ended December 31, 2018 was $465,415, versus $133,848 for the same period in 2017 (approximately 250% more). Net revenue for the year ended December 31, 2018 was $1,381,251 compared to $382,934 in 2017 (factor of 3.6 more).
https://www.otcmarkets.com/stock/DLYT/news/Dais-Announces-Fourth-Quarter-and-Fiscal-2018-Year-End-Financial-Results-Reports-Continued-Revenue-Growth?id=224544
And guess what ? it will going to get even bigger!
Dais future revenue growth for 2019 is expected to be driven by:
Aqualyte nanomaterial sales through existing and new commercial partnerships;
NanoClear sales with 33 pilots currently installed;
ConsERV sales in North America, and through our partnership with Zhejiang Menred Environmental Tech Co., Ltd, (“Menred Group”); and
Qualifying strategic OEM relationships designed to ‘kick off’ the sales of the Company’s PolyCool™ product, which uses the Company’s nanomaterial for a new generation of safer, more efficient cooling towers with membrane condensing evaporation-based products.
Dais’s revenue growth in 2019 is projected to be driven by increases in:
? Aqualyte nanomaterial sales through existing and new commercial partnerships, such as the growing relationship between Dais and the Haier Group in Qingdao, China.
? Sales of ConsERV in North America and targeted international markets, such as the partnership between Dais and the Zhejiang Menred Environmental Tech Co., Ltd, (the “Menred Group”) in the Greater China market;
? Sales of NanoClear™ in China, where 33 pilots are currently located; and
? Strategic Original Equipment Manufacturer (“OEM”) relationship(s) for production and sales of the Company’s PolyCool™ product using Aqualyte to offer a new generation of safer, more efficient cooling towers while improving the performance of condensers with the addition of membrane evaporation technology.
DLYT Enters Second Agreement with Haier Group projected to be $73 million or more annually!!!!
DLYT should be valued at .05 minimum right now! So it's one time opportunity to catch her at this – just last year DLYT was valued at .08!!
DLYT Establish Subsidiary in China!!
The Company signaled, with the signing of this agreement, the need to have an in-country subsidiary to grow its business interests in China. The expansion is projected to come from a more concentrated focus to increase the sales (and servicing) of Aqualyte™ nanomaterial, NanoClear™ industrial waste water treatment systems, and ConsERV™ components or systems for heating, ventilating, and air-conditioning (HVAC) energy and CO2 savings
DLYT is reaching all corners of the world with their products and right now she's on the verge of becoming a massive global company with huge revenues Quarter after Quarter
took DLYT 005s starter
DLYT revenues just getting bigger and bigger!
~Net revenue for the quarter ended December 31, 2018 was $465,415, versus $133,848 for the same period in 2017 (approximately 250% more). Net revenue for the year ended December 31, 2018 was $1,381,251 compared to $382,934 in 2017 (factor of 3.6 more).
https://www.otcmarkets.com/stock/DLYT/news/Dais-Announces-Fourth-Quarter-and-Fiscal-2018-Year-End-Financial-Results-Reports-Continued-Revenue-Growth?id=224544
And guess what ? it will going to get even bigger!
Dais future revenue growth for 2019 is expected to be driven by:
Aqualyte nanomaterial sales through existing and new commercial partnerships;
NanoClear sales with 33 pilots currently installed;
ConsERV sales in North America, and through our partnership with Zhejiang Menred Environmental Tech Co., Ltd, (“Menred Group”); and
Qualifying strategic OEM relationships designed to ‘kick off’ the sales of the Company’s PolyCool™ product, which uses the Company’s nanomaterial for a new generation of safer, more efficient cooling towers with membrane condensing evaporation-based products.
Dais’s revenue growth in 2019 is projected to be driven by increases in:
? Aqualyte nanomaterial sales through existing and new commercial partnerships, such as the growing relationship between Dais and the Haier Group in Qingdao, China.
? Sales of ConsERV in North America and targeted international markets, such as the partnership between Dais and the Zhejiang Menred Environmental Tech Co., Ltd, (the “Menred Group”) in the Greater China market;
? Sales of NanoClear™ in China, where 33 pilots are currently located; and
? Strategic Original Equipment Manufacturer (“OEM”) relationship(s) for production and sales of the Company’s PolyCool™ product using Aqualyte to offer a new generation of safer, more efficient cooling towers while improving the performance of condensers with the addition of membrane evaporation technology.
DLYT Enters Second Agreement with Haier Group projected to be $73 million or more annually!!!!
DLYT should be valued at .05 minimum right now! So it's one time opportunity to catch her at this – just last year DLYT was valued at .08!!
DLYT Establish Subsidiary in China!!
The Company signaled, with the signing of this agreement, the need to have an in-country subsidiary to grow its business interests in China. The expansion is projected to come from a more concentrated focus to increase the sales (and servicing) of Aqualyte™ nanomaterial, NanoClear™ industrial waste water treatment systems, and ConsERV™ components or systems for heating, ventilating, and air-conditioning (HVAC) energy and CO2 savings
DLYT is reaching all corners of the world with their products and right now she's on the verge of becoming a massive global company with huge revenues Quarter after Quarter
looking forward to upcoming catalysts
0013 new 52 wk highs... looks like 002s today
Looking forward to what next week brings
Great share structure for a 000
Got a feeling this is the start to something big.
Caught this eod Friday... old time runner to pennies
or you can sell them to me at 001... on bid! it will have its bounce. paytience
yes pb.. got your private message... I just gonna wait till dust settles
yes, got a trade out of it. thnx
lookin much better indeed
Both cfgn & MAXM crossed out is ready
DGTW added 15s and 16s myself
DGTW nice bottom forming here.. crypto @ 0016
excellent pb... BIPH revival. filings all done.. merger next
GM all... BIPH penny run coming.. keep on watch
Frustrating indeed
you should
thats some nice DD.. i was in hawaii couple of weeks ago. woulda checked it out if i knew back then
IDNG yes i picked some up as well
BIPH starting to come back to life here.. .filings should be hittin sometime soon on this Arcaro merger trade
weeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeee
PTOP 0055 hOd
0053s are here
Yes i saw ETFM 8k earlier.. settin up as well